Measles

Detailed Overview

Measles is one of the most highly communicable infectious diseases known, with a basic reproduction number (R0) of 12-18. Transmission occurs via airborne respiratory droplets that can remain suspended in the air for up to two hours. While safe and highly effective live-attenuated vaccines (MMR) exist, declining vaccination rates in some communities have led to resurgent outbreaks. The disease induces a state of profound immune amnesia, leaving the patient susceptible to severe secondary bacterial infections (like pneumonia), which are the leading cause of measles-related mortality.

Epidemiology & Demographics

Primarily affects unvaccinated children. Remains a leading cause of vaccine-preventable deaths globally (~130,000 deaths annually). Endemic in parts of Africa and Asia. In developed nations, outbreaks occur in tight-knit unvaccinated communities.

Etiological Mechanism

Infection by the Measles virus, a single-stranded, negative-sense RNA virus of the Paramyxoviridae family.

Primary Causes

Airborne transmission via inhalation of infectious aerosolized droplet nuclei from an infected person coughing or sneezing.

• Unvaccinated Status: The most critical risk factor. Missing the 2-dose MMR vaccine series.
• Vitamin A Deficiency: Associated with much higher rates of severe complications and mortality.
• Immunodeficiency: HIV/AIDS or leukemia patients are at risk for severe, fatal disease, even without a rash.

The virus infects alveolar macrophages and dendritic cells in the respiratory tract. It uses CD150 (SLAM) and Nectin-4 receptors to enter host cells. It spreads to regional lymph nodes, causing a primary viremia, then to the reticuloendothelial system. A secondary, massive viremia distributes the virus to the skin, conjunctiva, respiratory tract, and distant organs. The rash is actually a delayed type hypersensitivity reaction caused by cytotoxic T-cells attacking virus-infected endothelial cells in the skin. The virus destroys memory lymphocytes, leading to immune amnesia that lasts for months to years, severely dampening host immunity.

Characteristic Clinical Presentation

• Prodrome (The 3 Cs): Cough (severe, barking), Coryza (runny nose), Conjunctivitis (red, watery eyes).
• High Fever: Steadily rising fever, peaking as high as 104F (40C) when the rash appears.
• Photophobia: Sensitivity to light, accompanying the conjunctivitis.
• Maculopapular Rash: Non-itchy, red, flat/bumpy rash starting on the face/hairline and spreading downward to the trunk and limbs.

Physical Examination Signs

• Koplik Spots: Tiny bluish-white dots on an erythematous base on the buccal mucosa (inside cheeks), appearing 48 hours before the rash.
• Cephalocaudal spread of the exanthem (rash begins at hairline, moves to feet over 3 days).
• Generalized lymphadenopathy.

• Pneumonia: Most common cause of death. Can be primary viral giant-cell pneumonia or secondary bacterial.
• Otitis Media: Most common complication, occurring in 1 in 10 children, potentially causing hearing loss.
• Acute Encephalitis: Occurs in 1/1,000 cases, leading to seizures, deafness, or permanent brain damage.
• Subacute Sclerosing Panencephalitis (SSPE): A rare, fatal, progressive degenerative neurological disease occurring 7-10 years post-infection.

Diagnostic Criteria & Guidelines

Often diagnosed clinically during outbreaks. Confirmed by detecting Measles-specific IgM antibodies in serum, or by detecting viral RNA via RT-PCR of throat or nasopharyngeal swabs.

Differential Diagnosis

• Rubella (German Measles - milder fever, no Koplik spots, faster rash spread)
• Roseola Infantum (HHV-6 - high fever that breaks abruptly right before the rash appears)
• Kawasaki Disease
• Drug Eruption

Laboratory Tests & Biomarkers

• Measles IgM Antibody: Positive. Appears within 3 days of rash onset and peaks at 14 days.
• Complete Blood Count (CBC): Leukopenia (decreased WBCs), severe lymphopenia, and thrombocytopenia.

Imaging Modalities & Findings

• Chest X-Ray:

• Incubation
  10-14 days. Asymptomatic viral replication.
• Prodrome
  3-4 days. High fever, the 3 Cs, and Koplik spots. Patient is highly contagious.
• Exanthem
  5-6 days. Maculopapular rash erupts and spreads downward. Fever peaks.
• Recovery
  Rash fades in the same downward order, leaving a brownish discoloration and fine desquamation (peeling).

Second-Line & Adjunctive Therapy

Treatment of secondary bacterial complications (e.g., Amoxicillin for otitis media or Ceftriaxone for secondary pneumonia). Ribavirin may be considered in severe cases in immunocompromised patients, though efficacy is unproven.

Surgical & Procedural Management

None.

Recommended Lifestyle Changes

• Strict airborne isolation until 4 days after the onset of the rash.
• Dim lighting in the room to help with photophobia.
• Encourage fluid intake to prevent dehydration.

Patient Counseling & Advice

Explain that the disease must run its course over about 2 weeks. Warn parents to look out for signs of pneumonia (rapid breathing) or encephalitis (excessive sleepiness, seizures) and to seek immediate care if they occur.

Follow-Up & Monitoring Schedule

Clinical monitoring for complete resolution of fever. Post-measles patients remain susceptible to other infections for several months due to immune amnesia.

Preventive Strategies

Universal immunization with the live-attenuated MMR vaccine. First dose at 12-15 months; second dose at 4-6 years. Post-exposure prophylaxis with vaccine within 72 hrs or IVIG within 6 days for high-risk contacts.

Most recover fully with lifelong immunity. However, mortality is high (up to 10%) in malnourished populations or immunocompromised patients.